Oncomine Clinical Research Grants

Code of Conduct for Evaluators - 2023
1. The task of the Evaluator is to participate in a confidential, fair, and impartial evaluation of each proposal submitted to the Oncomine Clinical Research Grants program according to the procedures described in this “Code of Conduct”. He/she must use his/her best endeavors to participate in each Evaluation in accordance with this “Code of Conduct”, follow any instructions given by the Oncomine Clinical Research Grant Office to this end, and deliver a constant and high quality of work in respect of each Evaluation.

2. The Evaluator works as an independent person. He/she is deemed to work in a personal capacity in respect of each Evaluation and, in performing an Evaluation, does not represent any organization nor is prohibited by any organization from providing the Evaluation.

3. The Evaluator must sign the Declarations of “Confidentiality”, “Conflict of Interest” and “Compliance with Code of Conduct” before commencing work on any Evaluation and in particular prior to reviewing any Evaluation documents or processing data by which he/she agrees to abide by the terms of the present “Code of Conduct”.

4. Throughout an Evaluation process, the Evaluator commits him/herself to strict confidentiality and impartiality concerning his/her task of providing an Evaluation.

5. If an Evaluator has a conflict of interest in respect of a proposal, he/she must declare such fact to Oncomine Clinical Research Grant Office as soon as he/she becomes aware of this and agrees to stop all work on evaluating the particular proposal if asked to do.

6. Evaluators shall not discuss any proposal or its contents or divulge any data obtained through the Evaluation process whether directly or indirectly to any person, firm, or company or otherwise without the express prior written consent of the Oncomine Clinical Research Grant Office.

7. Evaluators may not communicate with applicants who are the subject of any Evaluation and may not contact third parties in connection with any Evaluation, except in hearings organized by the Oncomine Clinical Research Grant Office as part of the Evaluation process. No proposal may be amended during an evaluation. Evaluators’ advice to the Oncomine Clinical Research Grant Office on any proposal may not be communicated to the applicants or to any other person.

8. Where it has been decided that proposals are to be posted or made available electronically to evaluators, who then work from their own or other suitable premises, the Evaluator will be held personally responsible for maintaining the confidentiality of any and all documents or electronic files sent as part of the Evaluation process and for returning, erasing or destroying all such documents unless otherwise instructed by the Oncomine Clinical Research Grant Office.

9. The Evaluation must take place only in the country of residence/work of the Evaluator which is stated in the Curriculum Vitae and the “Declaration of Confidentiality”.

10. Evaluators may seek further information (for example through the internet, specialized databases, or otherwise) in order to allow them to complete their Evaluation of a proposal, provided that the obtaining of such information is in accordance with the terms of this “Code of Conduct”.

medical.affairs@thermofisher.com
11. Evaluators are always required to comply strictly with any rules of the Oncomine Clinical Research Grant Office for ensuring the confidentiality of the Evaluation process and its outcomes. In addition to any remedies available to the Oncomine Clinical Research Grant Office for failure to comply with this “Code of Conduct” and any other rules, the Oncomine Clinical Research Grant Office may also exclude the Evaluator from any current and/or future Evaluation process without compensation.

12. Evaluators shall process data, at all times, in accordance with all applicable personal data laws and solely for the purposes of the Evaluation process in accordance with this “Code of Conduct” and in any manner specified from time to time by the Oncomine Clinical Research Grant Office in writing and for no other purpose except with the express prior written consent of the Oncomine Clinical Research Grant Office.

13. Evaluators shall inform the Oncomine Clinical Research Grant Office immediately if an individual applicant (who is the subject of any proposal provided to an Evaluator for Evaluation) seeks to exercise any of his/her rights under applicable data protection laws with an Evaluator directly. The Evaluator hereby agrees to assist the Oncomine Clinical Research Grant Office with all data information requests received from any such individual.